Page last updated: 2024-11-06

mitomycin and Thrombophlebitis

mitomycin has been researched along with Thrombophlebitis in 1 studies

Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.

Thrombophlebitis: Inflammation of a vein associated with a blood clot (THROMBUS).

Research Excerpts

ExcerptRelevanceReference
"BMS-181174 has anti-cancer activity but, because of its toxicity, particularly pneumonitis and thrombophlebitis, no phase II studies are planned."2.69Phase I study of the mitomycin C analogue BMS-181174. ( Ganesan, TS; Green, JA; Harris, AL; LaCreta, FP; Macaulay, VM; McKinley, L; O'Byrne, KJ; Philip, PA; Talbot, DC; Winograd, B, 1998)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Macaulay, VM1
O'Byrne, KJ1
Green, JA1
Philip, PA1
McKinley, L1
LaCreta, FP1
Winograd, B1
Ganesan, TS1
Harris, AL1
Talbot, DC1

Trials

1 trial available for mitomycin and Thrombophlebitis

ArticleYear
Phase I study of the mitomycin C analogue BMS-181174.
    British journal of cancer, 1998, Volume: 77, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Female; Heart; Humans; Kidney; Lung; Male; Middle Ag

1998